Immunochemistry analysers are only now beginning to replace clinical chemistry and immunoassay analysers. Manufacturers are developing several alternatives for laboratories with varying workloads, personnel and budgets. Test menu and configuration offerings differ from manufacturer to manufacturer and new or improved assays are being added to test menus incrementally.
New analysis from Frost & Sullivan (drugdiscoverytechnologies.frost.com), European Immunochemistry Analysers Market, estimates that the market will be worth $164.7 million in 2007 and will reach $412.4 million by 2012.
"Even while the majority of the segments in the clinical laboratory analyser market, including clinical chemistry, haematology and urinalysis, are mature and have limited capacity for further growth, the newly developed segments of integrated analysers such as immunochemistry are experiencing high growth and contributing to overall market expansion," notes Frost & Sullivan Programme Manager Dr. Fiona Rahman. "Segments such as immunochemistry are experiencing steady demand due to an increase in test menus, particularly in cardiac and tumour assays."
With the recent introduction of integrated analysers that combine chemistry and immunoassay on one platform, the number of chemistry analysers purchased is projected to decline gradually. Immunochemistry analysers have the advantage of offering two analysers on one platform, resulting in their rapid adoption by laboratories.
Feedback has shown that laboratories are investing in immunochemistry analysers as they provide a growing range of tests for thyroid function, cardiac and cancer markers, fertility/reproductive markers, infectious disease and retroviral markers, metabolic markers and therapeutic drug monitoring. Immunochemistry systems analyse blood, saliva and urine and utilise several methodologies including enzyme immunoassay (EIA), coated microplate, chemiluminescence and fluorescence.
However, clinical laboratories are often hesitant to switch to a different brand of analysers due to the costs associated with the transition, which can involve retraining staff, restandardising practices and updating data management systems. Occasionally, even when laboratory managers and personnel are dissatisfied with their current instrument or service, they baulk at purchasing another manufacturer's product because the decision process and implementation can take a long time.
"Due to laboratory consolidation, the immunochemistry analyser market relies heavily on system replacements in order to generate revenue; manufactures have had to generate sales by replacing old clinical chemistry or immunoassay systems with integrated analysers or have had to win clients from other vendors," explains Dr. Rahman. "As competition becomes aggressive, analyser vendors continue to experience difficulties in increasing their customer base and demonstrating the benefits of immunochemistry analysers."
To further exacerbate the effects of this challenge, many laboratories resist buying new, expensive, high-technology immunochemistry analysers and are urgently attempting to achieve maximum returns on their investments.
"In light of increasing revenues from immunochemistry analyser sales, manufacturers should promote pre and post sample management and integration options to boost revenue streams from instrumentation sales," advises Dr. Rahman. "Additionally, customers should be encouraged to upgrade to integrated immunochemistry systems to increase productivity and reduce labour costs in the long term."
Enhanced levels of automation will also result in customers being tied down to a single vendor, while allowing vendors to successfully generate more long-term revenues from a single customer site.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the investment analysis and growth opportunities in the European immunochemistry analysers market, then send an email to Patrick Cairns, Corporate Communications, at patrick.cairns[.]frost.com, with your full name, company name, title, telephone number, fax number, and email address. Upon receipt of the above information, an overview will be sent to you by email.
European Immunochemistry Analysers Market is part of the Drug Discovery & Clinical Diagnostics Growth Partnership Service programme, which also includes research in the following markets: European Coagulation Diagnostics Markets, European IVD Market and European Haematology Diagnostic Market and European Clinical Diagnostics Automation Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.